Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
Pancreatic Cancer|Cancer
RADIATION: Carbon Ion|DRUG: Gemcitabine + Cisplatin|DRUG: Gemcitabine + Capecitabine|DRUG: Gemcitabine + Erlotinib|DRUG: Gemcitabine|RADIATION: Photon
Dose-limiting toxicity, Any CTCAE v. 4.03 non-hematologic adverse event of grade 3 or higher or any hematologic adverse event of grade 4 or higher, occurring within 90 days of the start of radiotherapy and deemed to be related to carbon ion radiotherapy., 90 days
Any grade 2 or higher treatment-related toxicity, scored using CTCAE v. 4.0, Any grade 2 or higher treatment-related toxicity, scored using CTCAE v. 4.0, through study completion, an average of 1 year|Radiographic changes following completion of study therapy (RECIST v. 1.1), Radiographic changes following completion of study therapy (RECIST v. 1.1), through study completion, an average of 1 year|Overall survival duration, The length of time from study inclusion until death from any cause, through study completion, an average of 1 year|Progression-free survival duration, The length of time from study inclusion until death from any cause or disease progression at any site, through study completion, an average of 1 year|The impact in terms of overall quality of life of radiation therapy as assessed by the QLQ-C30 questionnaire, Quality of life will be assessed at various time points using the European Organisation for Research and Treatment of Cancer 30 items dealing with fatigue, pain, nausea and vomiting, general condition and social, emotional and cognitive functions. It is currently used in many cancer related clinical trials., through study completion, an average of 1 year
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.